Epigenomics AG / Key word(s): Corporate Action 30.08.2013 15:40 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin, Germany, August 30, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces that upon […]
Year: 2013
30. August 2013
Epigenomics AG: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG issues EUR 500,000 in convertible bonds to YA Global Master SPV Ltd.
Read more
19. August 2013
Epigenomics AG: Epigenomics AG secures financing of up to EUR 5m
Epigenomics AG / Key word(s): Corporate Action 19.08.2013 / 08:30 Berlin, Germany, and U.S.A., August 19, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced that it has entered into an agreement with YA Global Master SPV Ltd. (‘Yorkville’) through which it secured a convertible bond financing […]
18. August 2013
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG secures financing of up to EUR 5m
Epigenomics AG / Key word(s): Corporate Action 18.08.2013 20:20 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin, Germany, August 18, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces that it […]
07. August 2013
Epigenomics AG: Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): Half Year Results 07.08.2013 / 08:30 Berlin, Germany, and U.S.A., August 7, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30. Revenue in Q2 2013 increased […]
22. July 2013
Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
Epigenomics AG / Key word(s): Study 22.07.2013 / 10:30 Press release Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial – CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates – Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC […]
09. July 2013
Epigenomics AG: Epigenomics Establishes American Depositary Receipt (ADR) Program
Epigenomics AG / Key word(s): Miscellaneous 09.07.2013 / 15:00 Epigenomics Establishes American Depositary Receipt (ADR) Program Epigenomics ADRs can be traded on US over-the-counter (OTC) market effective as of July 9, 2013 ADR ticker symbol EPGNY 1 ADR represents 5 ordinary company shares Berlin, Germany, and U.S.A., July 9, 2013 – Epigenomics AG (Frankfurt Prime […]